QLS2309
/ Qilu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 16, 2025
A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=186 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
New P1 trial • Hematological Malignancies • Oncology
1 to 1
Of
1
Go to page
1